These include studies of retatrutide in: Obesity Type 2 diabetes Obstructive sleep apnea Chronic low back pain Cardiovascular outcomes Renal outcomes Liver disease (MASLD) More than 5,800 people are enrolled across the Phase 3 program, making retatrutide one of the most thoroughly tested weight-loss drugs in development
GLP-1 medications serve a dual purpose in our practice, both as stand-alone therapies and as part of a comprehensive plan for patients preparing for bariatric surgery
Additionally, you must have one or more weight-related health conditions, such as high blood pressure or heart disease, and have previously tried other weight management programmes without success
Walking is encouraged early on to support circulation, though it is important to avoid heavy lifting or strenuous movement
People are using them for weight loss, biohacking, and fitness
IRB 20203414 Study (84%) standard mode Data on file